QQQ0.53%

Trending

NBIS9.16%

home Symbol QUREnews

QUREuniQure NV

$48.48

$21.49

(79.62%)

Today

Updated: 03:30 PM EDT

News·QURE Stock Surges Over 70% After FDA Softens Stance On Huntington’s Disease Gene Therapy

EarningsJul 29

Mkt Cap$1.69B

Vol16.73M

Fundamentals

Mkt Cap

$1.69B

52W High

$71.50

52W Low

$8.73

PE Ratio

-7.68

Avg. Volume

EPS (Annual)

-$3.46

Rev/Employee

$72,841.63

Earnings

Jul 29

Extremely Bullish Sentiment

How do you feel about QURE?

Info

News

all

press releases

Technological Innovations to Wage War Against Some of Medicine's Toughest Diseases

The biotechnology space is delivering a steady stream of potentially market-moving developments this week as companies across oncology, neuroscience, gene therapy, medical devices, and synthetic biology delivered significant regulatory, clinical, and commercial updates. $NTHI, $QURE, $ICCM, $CLPT, $ELTX, $AZTR

24-7 Market News

More News

QURE Stock Surges Over 70% After FDA Softens Stance On Huntington’s Disease Gene Therapy

uniQure said that the U.S. Food and Drug Administration is willing to consider three years of data as the primary basis for a biologics license application of AMT-130.

Stocktwits

Considering Uniqure NV (QURE) Stock? Read the AMT-130 Message

Considering Uniqure NV (QURE) Stock? Read the AMT-130 Message...

Yahoo! Finance: News

REPL, QURE Stocks Rise Amid Makary’s Reported Resignation As FDA Chief

The New York Times reported that Makary’s departure was driven in large part by his strong opposition to the administration’s decision to authorize fruit-flavored e-cigarettes.

Stocktwits

REPL, QURE, MRNA Soar On Reports Trump Will Fire FDA’s Marty Makary

The Wall Street Journal reported on the plans on Friday, citing people familiar with the matter, while noting that other top administration officials believe Makary is struggling to manage his agency.

Stocktwits

uniQure Q1 Earnings Call Highlights

uniQure (NASDAQ:QURE) executives outlined progress and upcoming regulatory milestones for lead Huntington's disease gene therapy candidate AMT-130 during the company's first-quarter 2026 earnings call, while also providing updates across its epilepsy and Fabry programs and reviewing quarterly financ...

MarketBeat

uniQure (NASDAQ:QURE) Issues Quarterly Earnings Results

uniQure (NASDAQ:QURE - Get Free Report) issued its quarterly earnings results on Tuesday. The biotechnology company reported ($0.85) EPS for the quarter, topping the consensus estimate of ($0.88) by $0.03. The company had revenue of $3.56 million during the quarter, compared to analysts...

MarketBeat

uniQure (QURE) Reports Q1 Loss, Misses Revenue Estimates

uniQure (QURE) delivered earnings and revenue surprises of +2.86% and -48.75%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Zacks

uniQure (NASDAQ:QURE) Shares Up 6.3% - Still a Buy?

uniQure (NASDAQ:QURE) Stock Price Up 6.3% - Time to Buy...

MarketBeat

Jennison Associates LLC Boosts Stake in uniQure N.V. $QURE

Jennison Associates LLC raised its position in shares of uniQure N.V. (NASDAQ:QURE - Free Report) by 37.2% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 1,371,190 shares of the biotechnology company's s...

MarketBeat

...

Advertisement|Remove ads.